ETHNIC VARIATIONS IN ANTIDEPRESSANT RESPONSE IN AFRICAN AMERICANS

非裔美国人抗抑郁反应的种族差异

• 批准号: 7381048
• 负责人: HECTOR FRANKLIN MYERS
• 金额: $ 3.94万
• 依托单位: CHARLES R. DREW UNIVERSITY OF MED & SCI
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7381048
• 关键词: ETHNIC; VARIATIONS; ANTIDEPRESSANT; RESPONSE; AFRICAN

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this collaborative, multi-site (King-Drew Medical Center, Harbor-UCLA Medical Center and Cedars-Sinai Medical Center) study is to examine the predective value of genetic polymorphism in 200 African American and 200 Caucasina subject who meet DSM-IV criteria for major depression when treated with the antidepressant citolopram (CIT). Recent advances in molecular biology and pharmacogenetics have contributed substantially to the understanding of the genetic control of the pharmacogenetics of the cytochrome P-450 enzymes, as well as the neurotransmitter transporters (therapeutic targets of most antidepressants), tools are now available to enable us to systematically response (kalow, 1992; Lin et al., 1993). In order to pursue these goals, this application proposes to contuct a prospective clinical trail of the safety and efficacy of citalopram (Celexa) (CIT), which is the most selective serotonin reuptake inhibitor (SSRI) that is currently available on the U.S. market (Stahl, 1998). CIT biotransformation is mediated pimarilty by CYP2C19 (Catterson & Preskorn, 1996).

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。这项多中心协作研究（King-Drew 医疗中心、Harbor-UCLA 医疗中心和 Cedars-Sinai 医疗中心）的目的是检查基因多态性对 200 名非裔美国人和 200 名符合 DSM- 的白种人受试者的预测价值。使用抗抑郁药西托普兰 (CIT) 治疗时重度抑郁症的 IV 标准。分子生物学和药物遗传学的最新进展极大地促进了对细胞色素 P-450 酶以及神经递质转运蛋白（大多数抗抑郁药的治疗靶标）的药物遗传学的遗传控制的理解，现在可以使用工具来使我们能够系统响应（kalow，1992；Lin 等，1993）。为了实现这些目标，本申请建议对西酞普兰（Celexa）（CIT）的安全性和有效性进行前瞻性临床试验，西酞普兰是目前在美国市场上销售的最具选择性的血清素再摄取抑制剂（SSRI）。斯塔尔，1998）。 CIT 生物转化是由 CYP2C19 介导的 pimarilty (Catterson & Preskorn, 1996)。